Novavax gets a new CEO

Rockville-based Novavax has announced that Stanley Erck, its former executive chairman, is taking over as the company's new CEO. Prior to joining Novavax, Erck was CEO of Iomai Corporation, which went public and eventually merged with Intercell. Erck is replacing Rahul Singhvi, who served as the company's CEO for six years. Novavax didn't explain why the change was made, but a board member said the company wishes Singhvi, "nothing but the best in his future endeavors." HHS recently granted the developer a contract worth up to $179.1 million to fund research on seasonal and pandemic influenza vaccines. Release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.